시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 비정형 용혈성 요독 증후군(aHUS) 치료 시장 보고서(2025년)
Atypical Hemolytic Uremic Syndrome Treatment Global Market Report 2025
상품코드 : 1760470
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

비정형 용혈성 요독 증후군(aHUS) 치료 시장 규모는 향후 수 년간 강력한 성장이 전망됩니다. 이용 가능성 증가, 진단 기술의 향상 등의 요인에 의한 것으로 예측됩니다. 예측 기간에 있어서의 주요한 동향에는 차세대 보체 억제제, 디지털 헬스 모니터링과 AI 툴, AI 주도의 신약, 맞춤형 의료, 제노타이핑과 바이오마커에 근거한 진단 등이 있습니다.

표적 치료에 대한 수요 증가는 비정형 용혈성 요독 증후군(aHUS) 치료 시장의 성장을 가속할 것으로 예측됩니다. 수요가 증가하고 있는 것은 보다 정확한 치료를 보다 적은 부작용으로 제공할 수 있기 때문에 환자의 결과가 개선해, 종래의 광범위한 치료에 대한 대안을 제공할 수 있기 때문입니다. 비정형 용혈성 요독 증후군의 경우, 질병의 주요 원인인 보체 시스템의 과도한 활성화를 차단하여 표적 치료가 효과적입니다. 이것에 의해 혈관이나 신장에의 데미지를 경감하는 적정한 개입이 가능하게 됩니다. 2023년 10월 NHS 잉글랜드는 잉글랜드에서 1,100만 건의 호르몬 대체 요법(HRT) 품목이 처방되었는데, 이는 2021-22년 대비 47% 증가한 수치이며, 약 230만명의 환자가 처방을 받고 전년 대비 29% 증가했다고 보고했습니다. 그 결과 표적요법에 대한 수요 증가가 비정형 용혈성 요독 증후군(aHUS) 치료 시장의 성장을 가속하고 있습니다.

비정형 용혈성 요독 증후군(aHUS) 치료 시장의 주요 기업은 표적 보체 억제를 강화하고 환자의 결과를 개선하기 위해 모노클로 날 항체 의약과 같은 최첨단 치료법의 개발에 주력하고 있습니다. 관여하는 특정 단백질을 특이적으로 표적으로 결합함으로써 유해한 병원체와 싸우는 면역계의 능력을 모방하는 실험실에서 제작된 단백질입니다. Pharma India Limited는 인도에서 에크리주맙(솔리리스로 판매)의 수입, 판매, 유통 승인을 중앙의약품 표준관리기구(CDSCO)로부터 취득했습니다. 이 단일 클론 항체는 보체 단백질 C5에 특이적으로 결합하여 그 절단을 방지하고 면역 매개 세포 손상을 일으키는 말단 보체 복합체의 형성을 차단합니다. 에클리주맙은 보체 개재성 장애를 저지함으로써 발작성 야간 헤모글로빈뇨증(PNH), 비정형 용혈성 요독 증후군(aHUS), 전신성 중증근무력증, 시신경 척수염 스펙트럼 장애 같은 희귀 및 중증 질환을 치료하는 데 사용됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening condition marked by abnormal blood clotting, which leads to damage in small blood vessels and results in hemolytic anemia, low platelet count, and kidney injury. It is often caused by genetic mutations or dysregulation in the complement system, leading to uncontrolled inflammation and vascular damage.

The main treatment options for atypical hemolytic uremic syndrome include complement inhibitors, plasma exchange therapy, supportive care, and antibiotics. Complement inhibitors are therapeutic agents that block or modulate the activation of the complement system, a critical component of the immune system involved in inflammation, immune response, and cell lysis. These inhibitors are administered through various routes, such as intravenous, subcutaneous, and oral. Technologies involved in the treatment include genetic testing and diagnostic tools, real-time monitoring and complement activation technologies, treatment delivery systems, and digital health solutions. These are used in various healthcare settings, including specialty clinics, home care environments, and ambulatory care centers.

The atypical hemolytic uremic syndrome treatment market research report is one of a series of new reports from The Business Research Company that provides atypical hemolytic uremic syndrome treatment market statistics, including atypical hemolytic uremic syndrome treatment industry global market size, regional shares, competitors with atypical hemolytic uremic syndrome treatment market share, detailed atypical hemolytic uremic syndrome treatment market segments, market trends and opportunities, and any further data you may need to thrive in the atypical hemolytic uremic syndrome treatment industry. This atypical hemolytic uremic syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The atypical hemolytic uremic syndrome treatment market size has grown strongly in recent years. It will grow from $1.63 billion in 2024 to $1.75 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth during the historic period can be attributed to several factors, including an increase in clinical trials, growing awareness of the disease, government support for research, enhanced diagnostic capabilities, and a rising incidence of the disease.

The atypical hemolytic uremic syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $2.34 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth during the forecast period can be attributed to factors such as government support initiatives, a focus on complement dysregulation, growing patient awareness, increased availability of treatments, and improved diagnostic techniques. Key trends in the forecast period include next-generation complement inhibitors, digital health monitoring and AI tools, AI-driven drug discovery, personalized medicine, and genotyping and biomarker-based diagnostics.

The increasing demand for targeted therapies is expected to drive the growth of the atypical hemolytic uremic syndrome (aHUS) treatment market. Targeted therapies are medical treatments that specifically focus on and disrupt the molecular pathways involved in disease progression. The growing demand for these therapies stems from their ability to deliver more precise treatments with fewer side effects, leading to improved patient outcomes and offering alternatives to traditional, broader treatments. In the case of atypical hemolytic uremic syndrome, targeted therapies work by blocking the overactivation of the complement system, which is the primary cause of the disease. This allows for precise interventions that reduce damage to blood vessels and kidneys. For example, in October 2023, NHS England reported that 11 million hormone replacement therapy (HRT) items were prescribed in England, a 47% increase from 2021-22, with approximately 2.3 million patients receiving prescriptions, marking a 29% year-on-year rise. Consequently, the increasing demand for targeted therapies is fueling the growth of the atypical hemolytic uremic syndrome treatment market.

Key players in the atypical hemolytic uremic syndrome treatment market are focusing on developing cutting-edge therapies, such as monoclonal antibody drugs, to enhance targeted complement inhibition and improve patient outcomes. Monoclonal antibodies are laboratory-engineered proteins that mimic the immune system's ability to combat harmful pathogens by specifically targeting and binding to certain proteins involved in disease mechanisms. For example, in January 2025, AstraZeneca Pharma India Limited, a biopharmaceutical company based in India, received approval from the Central Drugs Standard Control Organization (CDSCO) to import, sell, and distribute eculizumab (marketed as Soliris) in India. These monoclonal antibodies specifically bind to the complement protein C5, preventing its cleavage and thereby blocking the formation of the terminal complement complex responsible for immune-mediated cell damage. Eculizumab is used to treat rare and severe conditions such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis, and neuromyelitis optica spectrum disorder by preventing complement-mediated damage.

In October 2022, Amgen Inc., a US-based biotechnology company, acquired ChemoCentryx Inc. for approximately $3.7 billion. This acquisition is part of Amgen's strategy to expand its portfolio in the field of autoimmune and rare diseases by incorporating ChemoCentryx's innovative therapies and expertise in complement-based treatments. ChemoCentryx Inc., a US-based biopharmaceutical company, specializes in developing treatments for rare conditions, including atypical hemolytic uremic syndrome (aHUS).

Major players in the atypical hemolytic uremic syndrome treatment market are F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Amgen Inc., Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Alnylam Pharmaceuticals Inc., Vifor Pharma Ltd., Samsung Bioepis Co. Ltd., Fuji Pharma Co. Ltd., Aevitas Therapeutics Inc., Pharmasyntez JSC, Omeros Corporation, ChemoCentryx Inc., ISU Abxis Co. Ltd., Greenovation Biotech GmbH, Akari Therapeutics plc, NovelMed Therapeutics Inc., Eleva GmbH.

North America was the largest region in the atypical hemolytic uremic syndrome treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in atypical hemolytic uremic syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the atypical hemolytic uremic syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The atypical hemolytic uremic syndrome (aHUS) market consists of revenues earned by entities by providing services such as renal support and dialysis, genetic testing and counseling, long-term monitoring and follow-up. The market value includes the value of related goods sold by the service provider or included within the service offering. The atypical hemolytic uremic syndrome (aHUS) market also includes sales of immunosuppressive therapies, plasma exchange equipment, dialysis machines, and supportive care medications. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Atypical Hemolytic Uremic Syndrome Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on atypical hemolytic uremic syndrome treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for atypical hemolytic uremic syndrome treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The atypical hemolytic uremic syndrome treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Atypical Hemolytic Uremic Syndrome Treatment Market Characteristics

3. Atypical Hemolytic Uremic Syndrome Treatment Market Trends And Strategies

4. Atypical Hemolytic Uremic Syndrome Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Atypical Hemolytic Uremic Syndrome Treatment Growth Analysis And Strategic Analysis Framework

6. Atypical Hemolytic Uremic Syndrome Treatment Market Segmentation

7. Atypical Hemolytic Uremic Syndrome Treatment Market Regional And Country Analysis

8. Asia-Pacific Atypical Hemolytic Uremic Syndrome Treatment Market

9. China Atypical Hemolytic Uremic Syndrome Treatment Market

10. India Atypical Hemolytic Uremic Syndrome Treatment Market

11. Japan Atypical Hemolytic Uremic Syndrome Treatment Market

12. Australia Atypical Hemolytic Uremic Syndrome Treatment Market

13. Indonesia Atypical Hemolytic Uremic Syndrome Treatment Market

14. South Korea Atypical Hemolytic Uremic Syndrome Treatment Market

15. Western Europe Atypical Hemolytic Uremic Syndrome Treatment Market

16. UK Atypical Hemolytic Uremic Syndrome Treatment Market

17. Germany Atypical Hemolytic Uremic Syndrome Treatment Market

18. France Atypical Hemolytic Uremic Syndrome Treatment Market

19. Italy Atypical Hemolytic Uremic Syndrome Treatment Market

20. Spain Atypical Hemolytic Uremic Syndrome Treatment Market

21. Eastern Europe Atypical Hemolytic Uremic Syndrome Treatment Market

22. Russia Atypical Hemolytic Uremic Syndrome Treatment Market

23. North America Atypical Hemolytic Uremic Syndrome Treatment Market

24. USA Atypical Hemolytic Uremic Syndrome Treatment Market

25. Canada Atypical Hemolytic Uremic Syndrome Treatment Market

26. South America Atypical Hemolytic Uremic Syndrome Treatment Market

27. Brazil Atypical Hemolytic Uremic Syndrome Treatment Market

28. Middle East Atypical Hemolytic Uremic Syndrome Treatment Market

29. Africa Atypical Hemolytic Uremic Syndrome Treatment Market

30. Atypical Hemolytic Uremic Syndrome Treatment Market Competitive Landscape And Company Profiles

31. Atypical Hemolytic Uremic Syndrome Treatment Market Other Major And Innovative Companies

32. Global Atypical Hemolytic Uremic Syndrome Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Atypical Hemolytic Uremic Syndrome Treatment Market

34. Recent Developments In The Atypical Hemolytic Uremic Syndrome Treatment Market

35. Atypical Hemolytic Uremic Syndrome Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기